Ipamorelin 10mg

Ipamorelin is a synthetic peptide that is classified as a growth hormone secretagogue. It stimulates the production and release of growth hormone (GH) from the pituitary gland, which is responsible for various physiological processes. Ipamorelin works by binding to specific receptors in the hypothalamus and pituitary gland, increasing GH levels. This peptide is known for promoting muscle growth, reducing body fat, improving sleep quality, enhancing recovery, and supporting overall health and well-being. It is often used in research and clinical settings for potential therapeutic benefits.

Source: PubChem

• Peptide Sequence: Aib-His-D-2Nal-D-Phe-Lys
• Molecular Formula: C38H49N9O5
• Molecular Weight: 711.868 g/mol
• PubChem CID: 9831659
• CAS Number: 170851-70-4

1. Ipamorelin and Negative Corticosteroid Effects

Ipamorelin has been studied for its potential to reduce the negative side effects of corticosteroid treatment. Corticosteroids, such as prednisone, are commonly used to treat a variety of conditions but can have adverse effects on muscle tissue.

Research suggests that growth hormone (GH) can help counteract the catabolic effects of corticosteroids on amino-nitrogen metabolism. Ipamorelin, as a GH secretagogue, may potentially enhance GH levels and mitigate some of the negative effects of corticosteroid treatment on muscle tissue.

Glucocorticoids, a type of corticosteroid, have been found to increase muscle calcium levels, which can lead to muscle wasting. This effect may be attributed to stimulated store-operated calcium entry (SOCE).

2. Ipamorelin and Bone Health

Research indicates that Ipamorelin may positively affect bone mineral content (BMC) and bone density.

A study investigated the effects of Ipamorelin and GH-releasing peptide-6 (GHRP-6) on BMC and found that these growth hormone secretagogues may increase bone mineral content. Another study highlighted the specific growth hormone-releasing properties of Ipamorelin, suggesting its potential in promoting bone health.

Growth hormone plays a crucial role in bone remodeling, and clinical studies have demonstrated its importance in maintaining normal bone health. Ipamorelin may contribute to bone density and strength by stimulating the release of growth hormone.

Additionally, peptides, including Ipamorelin, have been explored for their potential in treating osteoporosis. Peptide treatments can help improve bone density, reduce the risk of fractures, and enhance overall bone health.

3. Ipamorelin and Muscle Growth

Ipamorelin has gained popularity among bodybuilders for its potential to promote muscle growth and increase strength. It is a powerful growth hormone-releasing peptide (GHRP) that may help build lean muscle mass, improve fat loss, and boost energy levels.

When used in combination with other peptides like CJC-1295, Ipamorelin can stimulate muscle development and enhance overall muscle mass. It is believed to release hormones into the bloodstream that contribute to improved muscle growth, cognitive function, and memory.

4. Ipamorelin and Diabetes

Research suggests that Ipamorelin may improve blood sugar levels and contribute to the prevention of diabetes.

One study investigated the mechanism of Ipamorelin-evoked insulin release and found that it stimulates insulin release through calcium channel and adrenergic receptor pathways. This suggests that Ipamorelin may positively affect insulin production and regulation.

Peptide therapy, including the use of Ipamorelin, is being explored as a potential treatment for diabetes. Peptides used in diabetes therapy mimic natural peptides in the body that regulate insulin production and blood sugar levels.

5. Studied for Treatment of Post-Operative Ileus

Post-operative ileus refers to a condition with a temporary impairment of normal bowel function following surgery. Managing post-operative ileus typically involves supportive care and the exclusion of more serious surgical conditions.

Studies have been conducted on the use of Ipamorelin for the treatment of post-operative ileus. One prospective, randomized, controlled, proof-of-concept study investigated the use of Ipamorelin for managing post-operative ileus after bowel resection surgery. The study compared intravenous infusions of 0.03-mg/kg Ipamorelin versus a placebo. Subanalyses suggested potential benefits from ipamorelin treatment, particularly in patients who underwent open laparotomy.

Source: PubMed

1. Amount of radiolabeled food remaining in stomach is lower in rats with POI after ipamorelin administration, even when compared to rats not suffering from POI.
2. The geometric location of the food is similar to rats without POI when rats with POI are given ipamorelin.
3. Location of radiolabeled food is more distal in GI tract, and similar to rats without POI, after ipamorelin is administered.

6. Ipamorelin as Ghrelin Receptor Probe

Ipamorelin is a synthetic peptidomimetic that acts on the ghrelin receptor. It has been studied for various purposes, including its potential as a ghrelin receptor probe. Here are some key findings from the research:

The ghrelin receptor has been found to exhibit high constitutive activity, suggesting its physiological importance as a regulator.

Another study investigated the efficacy of ipamorelin in accelerating gastric emptying by acting on the ghrelin receptor.

Peptidomimetic growth hormone secretagogue derivatives, including ipamorelin, have shown promise as PET probes for detecting diseases characterized by overexpression of the ghrelin receptor.

Ipamorelin specifically binds to the ghrelin receptor (or GH secretagogue receptor, GHSR) and displays growth hormone-releasing activity.

Ipamorelin may be considered neglected in research due to several factors. One possible reason is the focus on other more widely studied growth hormone secretagogues, such as GHRP-2 and GHRP-6. Additionally, the limited number of research studies on ipamorelin might be attributed to its status as a non-orphan drug, which means it may not receive the same level of attention or funding as drugs designated for rare diseases.

Another factor could be the relatively early stage of research on ipamorelin. While there have been some promising findings regarding its effects, further research is needed to fully understand its potential benefits and applications. The field of hormone research is vast, with many different compounds and pathways to explore, and resources may be allocated to other areas of study.

Please note that all the articles and product information provided on this website are intended for informational and educational purposes only.

The products offered on this platform are specifically designed for in-vitro studies, meaning they are conducted outside the body. It is important to clarify that these products are not medicines or drugs, and the FDA has not approved them for the prevention, treatment, or cure of any medical condition, ailment, or disease.

The above literature was researched, edited and organized by Dr. Logan, M.D. Dr. Logan holds a doctorate degree from Case Western Reserve University School of Medicine and a B.S. in molecular biology.

David E. Beck, MD, co-author of “Prospective, randomized, controlled, proof-of-concept study of the Ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients” specializes in colon and rectal surgery.

David E. Beck, MD is being referenced as one of the leading scientists involved in the research and development of Ipamorelin. In no way is this doctor/scientist endorsing or advocating the purchase, sale, or use of this product for any reason. There is no affiliation or relationship, implied or otherwise, between Peptide Shop and this doctor. The purpose of citing the doctor is to acknowledge, recognize, and credit the exhaustive research and development efforts conducted by the scientists studying this peptide. David E. Beck, MD is listed in [6] under the referenced citations.

1. K. Raun et al., “Ipamorelin, the first selective growth hormone secretagogue,” Eur. J. Endocrinol., vol. 139, no. 5, pp. 552–561, Nov. 1998. [PubMed]
2. N. B. Andersen, K. Malmlöf, P. B. Johansen, T. T. Andreassen, G. Ørtoft, and H. Oxlund, “The growth hormone secretagogue ipamorelin counteracts glucocorticoid-induced decrease in bone formation of adult rats,” Growth Horm. IGF Res. Off. J. Growth Horm. Res. Soc. Int. IGF Res. Soc., vol. 11, no. 5, pp. 266–272, Oct. 2001. [PubMed]
3. J. Svensson et al., “The GH secretagogues ipamorelin and GH-releasing peptide-6 increase bone mineral content in adult female rats,” J. Endocrinol., vol. 165, no. 3, pp. 569–577, Jun. 2000. [PubMed]
4. N. K. Aagaard et al., “Growth hormone and growth hormone secretagogue effects on nitrogen balance and urea synthesis in steroid treated rats,” Growth Horm. IGF Res. Off. J. Growth Horm. Res. Soc. Int. IGF Res. Soc., vol. 19, no. 5, pp. 426–431, Oct. 2009. [PubMed]
5. E. Adeghate and A. S. Ponery, “Mechanism of ipamorelin-evoked insulin release from the pancreas of normal and diabetic rats,” Neuro Endocrinol. Lett., vol. 25, no. 6, pp. 403–406, Dec. 2004. [PubMed]
6. D. E. Beck, W. B. Sweeney, M. D. McCarter, and Ipamorelin 201 Study Group, “Prospective, randomized, controlled, proof-of-concept study of the Ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients,” Int. J. Colorectal Dis., vol. 29, no. 12, pp. 1527–1534, Dec. 2014. [PubMed]
7. B. Greenwood-Van Meerveld, K. Tyler, E. Mohammadi, and C. Pietra, “Efficacy of ipamorelin, a ghrelin mimetic, on gastric dysmotility in a rodent model of postoperative ileus,” J. Exp. Pharmacol., vol. 4, pp. 149–155, Oct. 2012. [PubMed]
8. M. M. Fowkes, T. Lalonde, L. Yu, S. Dhanvantari, M. S. Kovacs, and L. G. Luyt, “Peptidomimetic growth hormone secretagogue derivatives for positron emission tomography imaging of the ghrelin receptor,” Eur. J. Med. Chem., vol. 157, pp. 1500–1511, Sep. 2018. [Science Direct]

ALL ARTICLES AND PRODUCT INFORMATION PROVIDED ON THIS WEBSITE ARE FOR INFORMATONAL AND EDUCATIONAL PURPOSES ONLY.

The products offered on this website are furnished for in-vitro studies only. In-vitro studies (Latin: in glass) are performed outside of the body.  These products are not medicines or drugs and have not been approved by the FDA to prevent, treat or cure any medical condition, ailment or disease.  Bodily introduction of any kind into humans or animals is strictly forbidden by law.